BETHEL, Conn., Dec. 30 /PRNewswire-FirstCall/ -- Aduromed Industries, Inc. , a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste, today announced Damien Tanaka, the Company’s Founder, Vice Chairman and Chief Development Officer, has decided to retire and tender his resignation both from the Company and Aduromed’s board effective December 31, 2008.
“Aduromed has positioned itself to expand its presence in the industry and achieve ambitious goals in the coming years, and I believe Scott Grisanti and his team are well-prepared to enhance the Company’s intellectual property, grow revenues, deliver profits and ultimately, shareholder value,” Mr. Tanaka explained. “After more than 16 years in nurturing the Company and with a professional team now in place to take the Company to the next level, I believe it is the appropriate time for me to retire and spend more time with my family before considering future endeavors.”
“Damien’s enthusiasm and entrepreneurial spirit helped to create significant technology which Aduromed will now leverage to take to the next level,” added Scott Grisanti, President and Chief Executive Officer of Aduromed. “He played an important role as the Founder and in developing our intellectual property, and setting the stage for the new business plan we will announce and execute beginning in 2009. We thank Damien for his many years of service. We wish him well in his retirement and in future efforts.”
About Aduromed Industries, Inc.
Aduromed Industries, Inc. is a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste. Aduromed’s flagship MedClean(R) Series systems are fully integrated, turnkey technology solutions that enable hospitals and other healthcare providers to safely, efficiently and cost-effectively convert bio-hazardous regulated medical waste into sterile, unrecognizable material suitable for disposal as municipal solid waste. Aduromed was founded in 1997 with corporate headquarters, research and development and distribution facilities located in Bethel, Connecticut. Further information on Aduromed can be found at http://www.aduromed.com and in filings with the Securities and Exchange Commission found at http://www.sec.gov.
Statements about our future expectations are “forward-looking statements” within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words “may,” “will,” “should,” “anticipate,” “believe,” “appear,” “intend,” “plan,” “expect,” “estimate,” “approximate,” and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2007, filed with the SEC on March 31, 2008, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.
CONTACT: Kevin Dunphy, Chief Financial Officer of Aduromed Industries,
Inc., +1-203-798-1080, kdunphy@aduromed.com; or Investors, Cameron Donahue
of Hayden IR, +1-651-653-1854, cameron@haydenir.com, for Aduromed
Industries, Inc.
Web site: http://www.aduromed.com/
